Leszek Szczepanski Selected Research

Hydromorphone (Dilaudid)

1/2013	Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
9/2010	A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leszek Szczepanski Research Topics

Disease

3	Rheumatoid Arthritis 08/2014 - 06/2004
2	Pain (Aches) 01/2013 - 09/2010
2	Infections 05/2006 - 06/2004
1	Rheumatic Diseases (Rheumatism) 08/2014
1	Chronic Pain 09/2010
1	Sleepiness 09/2010
1	Ulcer 04/2006

Drug/Important Bio-Agent (IBA)

2	Oxycodone (Oxycontin)FDA LinkGeneric 01/2013 - 09/2010
2	Hydromorphone (Dilaudid)FDA LinkGeneric 01/2013 - 09/2010
2	Rituximab (Mabthera)FDA Link 05/2006 - 06/2004
2	Methotrexate (Mexate)FDA LinkGeneric 05/2006 - 06/2004
1	tabalumabIBA 08/2014
1	Monoclonal AntibodiesIBA 08/2014
1	C-Reactive ProteinIBA 08/2014
1	B-Cell Activating FactorIBA 08/2014
1	Opioid Analgesics (Opioids)IBA 09/2010
1	GlucocorticoidsIBA 05/2006
1	Antirheumatic Agents (DMARD)IBA 05/2006
1	Biological ProductsIBA 05/2006
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2006
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2006
1	Esomeprazole (Nexium)FDA Link 04/2006
1	Proton Pump InhibitorsIBA 04/2006
1	Pharmaceutical PreparationsIBA 04/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2004

Therapy/Procedure

2	Therapeutics 09/2010 - 06/2004